Short answer
Sionna Therapeutics, Inc. (SION) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$30M
- −65.4% YoY · −11.6% QoQ
- EPS (diluted)
- −$0.65
- +99.8% YoY · −8.3% QoQ
Source: XBRL data from the Sionna Therapeutics, Inc. (SION) Q2 2026 10-Q on SEC EDGAR. USD.
Sionna Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product sales or other revenue
- Operating margin (loss) (100.0%) vs (100.0%) YoY; net loss $29.9M vs $18.1M
- Best-performing program NBD1 and combination development, R&D $11.8M vs $8.8M
- Cash, equivalents and marketable securities $268.3M; operating cash use $44.1M vs $34.4M
- Funding runway into 2028; additional capital needed as clinical-development expenses increase
Risk Factors
- No explicit new or changed risk factors identified; filing text is truncated before completion
- Clinical-stage losses: net loss $56.7 million and accumulated deficit $313.0 million as of June 30, 2026
- Regulatory approval risk: FDA may require additional preclinical studies or clinical trials before or after approval
- Combination-therapy risk: SION-719 and SION-451 programs face drug-drug interaction and unforeseen side-effect risks
- Liquidity risk: $268.3 million in cash, cash equivalents and marketable securities expected to fund operations into 2028
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Sionna Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.